

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**LISTING OF CLAIMS:**

**1-11. (cancelled)**

**12. (currently amended)** ~~Use of HMC box binding molecules for the preparation of therapeutic agents for the treatment of A~~  
method for treating vascular diseases related to endothelial and smooth muscle cells proliferation, said method comprising administering to a subject in need thereof the therapeutic agent of claim 16.

**13. (currently amended)** ~~Use of HMC box binding molecules for the preparation of therapeutic agents for the treatment of vascular diseases related to endothelial and smooth muscle cells proliferation~~The method according to claim 12, ~~characterised in that~~wherein the vascular diseases are due to atherosclerosis and/or restenosis after blood vessels damage.

**14. (currently amended)** ~~Use of HMC box binding molecules for the preparation of therapeutic agents for the treatment of vascular diseases related to endothelial and smooth muscle cells proliferation~~The method according to claim 12,

~~characterised in that~~wherein the vascular diseases are due to atherosclerosis and/or restenosis after blood vessels damage, including those events that occur after coronary and/or carotid angioplasty, with or without stent positioning, angiographic surgery, and surgery using catheters.

**15. (currently amended)** ~~Use of HMG box binding molecules~~The method according to claim 12, wherein said HMG box binding molecules belong tomolecule is chosen from the group comprising antibodies or antibodies fragments, inhibitors and four-way DNA.

**16. (currently amended)** ~~Therapeutic~~A therapeutic agent for the treatment of vascular diseases related to smooth muscle and endothelial cells proliferation~~characterised in that it comprises, said agent comprising a therapeutic active amount of a HMG box binding moleculesmolecule.~~

**17. (currently amended)** ~~Therapeutic~~The therapeutic agent for the treatment of vascular diseases related to smooth muscle and endothelial cells proliferation according to claim 16,wherein said molecules belong to the group comprising HMG box binding molecule is chosen from antibodies or antibodies fragments, inhibitors and four-way DNA and not sRAGE.

**18. (currently amended) Therapeutic**—The therapeutic agent for the treatment of vascular diseases related to smooth muscle and endothelial cells proliferation—~~characterised in that it comprises,~~ said agent comprising a therapeutic active amount of antagonist molecules having sequence homology with HMG box and being able to bind ~~the~~ a functional HMG box binding domain of the receptor.

**19. (currently amended) Therapeutic**—The therapeutic agent according to claim 16, ~~characterised in that it~~ wherein said agent is released by catheters, surgical instruments implants or stents.